Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05704725 | A Study to Evaluate ABP 938 and Aflibercept (Eylea®) in Participants With Chorioretinal Vascular Disease (CVD) | PHASE3 | COMPLETED | 49 | — | — | Jan 23, 2023 | Mar 24, 2023 | Feb 14, 2025 | 4 | United States |
A successful injection was defined by whether the retinal specialist administering the IVT injection answered 'yes' to the following question: Did the PFS allow for the safe and effective administration of the prescribed dose? Percentage of successful injections and Clopper-Pearson 95% Confidence Interval is reported.
| Arm | Type | Description |
|---|---|---|
| ABP 938 | EXPERIMENTAL | Participants will be randomized in a ratio of 2:1 to receive either a single IVT injection of ABP 938 in a PFS or a single injection of aflibercept in a PFS. |
| Aflibercept | EXPERIMENTAL | Participants will be randomized in a ratio of 2:1 to receive either a single IVT injection of ABP 938 in a PFS or a single injection of aflibercept in a PFS. |
| Name | Type | Description |
|---|---|---|
| ABP 938 | DRUG | IVT injection |
| Aflibercept | DRUG | IVT injection |
Inclusion Criteria * Must sign an IRB approved informed consent form before any study-specific procedures are initiated. * Men or women ≥18 years old. * Treatment-naïve or previously treated neovascular age-related macular degeneration, diabetic macular edema, macular edema following retinal vein o...